Joel M Gelfand Highlights Platelet RNA Signature in Psoriasis
Joel M Gelfand, Director Center for Clinical Sciences in Dermatology at University of Pennsylvania School of Medicine, shared a post on LinkedIn:
“An under investigated topic in psoriasis is its impact on platelets. Here, Michael Garshick demonstrates that even when psoriasis is well controlled with biologics platelets remain activated and have a newly discovered RNA signature that predicts future cardiovascular events.
Details here
Álvaro González Cantero has also recently demonstrated that patients with well controlled psoriasis have residual systemic inflammation
Details here
These findings provide more evidence that simply treating the skin may not be enough to lower CV risk and that more holistic multi-pronged approaches are needed. Note, I am a collaborator and author on both papers”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 12:05Kent H: The Lymphatic System – The Unsung Hero of Detox
-
Mar 12, 2026, 11:55Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia
-
Mar 12, 2026, 11:33Kymentie Ferdinande: New Insights Into Platelet Function and Thrombus Formation in Cirrhosis
-
Mar 12, 2026, 11:17Tareq Abadl: Why Do Some People Bruise And Bleed So Easily?
-
Mar 12, 2026, 11:15Matthew Flick: The Interplay of the Fibrinogen αC-Region, Hypofibrinogenemia, and GPVI in Arterial Thrombosis
-
Mar 12, 2026, 11:08Stephen Twumasi: The Impact of Hepatitis B Infection on the Coagulation System During Pregnancy
-
Mar 12, 2026, 11:05Robert Lufkin: One Minute of Wisdom from Robert Lustig on Cholesterol, Sugar, and Heart Disease